Juno Therapeutics (JUNO) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results
February 29, 2016 4:05 PM ESTOn track for approval of JCAR015 as soon as 2017 in relapsed/refractory adult ALL
First clinical milestone met for CD22 CAR T cell product candidate
Multiple trials enrolling using CAR/TCR product candidates to treat solid organ tumors
Celgene collaboration off to a strong start
Strong 2015 year end cash position of $1.22 billion
2016 cash burn guidance of $220 million to $250 million, with $170 million to $195 million in operating burn
Conference call to be held today at 5:00 p.m. Eastern Time
... More
